Jpmorgan Chase & CO Cardiol Therapeutics Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Cardiol Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,500 shares of CRDL stock, worth $3,975. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,500Holding current value
$3,975% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding CRDL
# of Institutions
45Shares Held
5.07MCall Options Held
5.2KPut Options Held
9.5K-
Tejara Capital LTD London, X01.77MShares$2.82 Million1.67% of portfolio
-
Advisor Shares Investments LLC Bethesda, MD1.17MShares$1.86 Million0.46% of portfolio
-
Mmcap International Inc. Spc Grand Cayman, E9796KShares$1.27 Million0.36% of portfolio
-
Lion Street Advisors, LLC273KShares$434,5160.19% of portfolio
-
Foundations Investment Advisors, LLC162KShares$257,5000.01% of portfolio
About Cardiol Therapeutics Inc.
- Ticker CRDL
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 61,942,500
- Market Cap $98.5M
- Description
- Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of cardiovascular disease (CVD). Its lead product is CardiolRx, which is in Phase II/III multi-national, randomized, double-blind, and placebo-controlled study to evaluate t...